Santarus, Inc. (NASDAQ:SNTS)

CAPS Rating: 5 out of 5

A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.


Player Avatar Stan1955 (63.28) Submitted: 1/16/2013 12:33:40 PM : Outperform Start Price: $12.43 SNTS Score: +130.34

Colitis is a very common problem and there will be a huge demand for this drug world wide. Insurance companies will pay big bucks to get the person off their sick beds and back to work.

Featured Broker Partners